Stock Analysis on Net
Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity 
Quarterly Data

Allergan Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013 Dec 31, 2012 Sep 30, 2012 Jun 30, 2012 Mar 31, 2012 Dec 31, 2011 Sep 30, 2011 Jun 30, 2011 Mar 31, 2011 Dec 31, 2010 Sep 30, 2010 Jun 30, 2010 Mar 31, 2010
Notes payable 0.58 0.48 0.55 0.57 0.53 0.37 0.53 0.62 0.53 0.46 0.49 1.01 0.99 0.96 0.97 0.43 0.34 0.22 0.17 0.23
Convertible notes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.75 7.73 7.45 8.09 0.00
Accounts payable 2.31 2.43 2.73 2.95 2.68 2.64 2.45 2.36 2.54 2.36 2.31 2.34 2.36 2.32 2.54 2.40 2.68 2.42 2.55 3.38
Accrued compensation 2.36 2.30 1.93 1.57 2.54 2.38 2.02 1.69 2.44 2.30 1.87 1.49 2.36 2.28 2.17 1.42 2.20 1.98 1.90 1.29
Accrued legal settlement expenses 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7.14 0.00 0.00
Other accrued expenses 7.29 8.24 7.59 6.55 5.65 6.24 6.31 6.75 6.42 6.69 6.44 6.32 5.52 5.72 6.02 5.63 5.26 5.06 4.97 5.09
Income taxes 0.00 0.00 0.00 0.00 0.37 0.17 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.25 0.55 0.27
Liabilities of discontinued operations 0.00 0.00 0.00 0.00 0.00 0.03 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Current liabilities 12.54% 13.46% 12.80% 11.64% 11.77% 11.83% 11.35% 11.48% 11.93% 11.84% 11.11% 11.16% 11.22% 11.29% 11.69% 17.63% 18.40% 24.51% 18.23% 10.27%
Long-term debt, excluding current maturities 16.80 17.93 19.03 19.54 19.84 20.72 21.75 22.78 16.48 17.01 17.47 17.44 17.81 18.53 19.17 18.27 18.47 18.10 11.41 11.51
Long-term convertible notes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.17
Other liabilities 8.14 7.48 6.35 7.01 7.21 7.20 7.50 7.77 7.72 8.37 8.45 8.29 8.30 7.52 5.83 5.70 5.59 4.88 4.74 4.94
Non-current liabilities 24.93% 25.42% 25.39% 26.56% 27.05% 27.91% 29.25% 30.56% 24.20% 25.38% 25.92% 25.73% 26.11% 26.05% 24.99% 23.98% 24.06% 22.98% 16.15% 24.62%
Total liabilities 37.47% 38.87% 38.18% 38.20% 38.82% 39.74% 40.60% 42.03% 36.13% 37.22% 37.03% 36.89% 37.33% 37.34% 36.69% 41.60% 42.45% 47.49% 34.39% 34.89%
Preferred stock, $.01 par value; none issued 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, $.01 par value 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04
Additional paid-in capital 27.01 27.90 29.06 29.15 28.68 29.62 30.76 31.90 31.60 32.03 32.56 32.17 32.46 33.30 34.30 33.79 33.89 32.49 35.33 35.87
Accumulated other comprehensive loss -3.29 -2.52 -1.97 -2.09 -2.14 -2.49 -2.92 -2.87 -2.66 -2.75 -2.98 -2.52 -2.84 -2.19 -1.27 -1.57 -1.84 -1.23 -2.14 -1.61
Retained earnings 47.48 46.47 46.76 44.69 43.94 43.01 42.27 40.67 41.75 40.43 39.06 36.10 34.90 33.63 32.11 27.98 26.79 23.77 34.97 32.76
Treasury stock, at cost -8.78 -10.82 -12.13 -10.04 -9.39 -10.19 -11.00 -12.03 -7.13 -7.25 -5.97 -2.94 -2.15 -2.40 -2.18 -2.11 -1.61 -2.85 -2.87 -2.23
Total Allergan, Inc. stockholders’ equity 62.45% 61.06% 61.74% 61.73% 61.12% 59.99% 59.14% 57.70% 63.59% 62.50% 62.71% 62.86% 62.40% 62.39% 63.00% 58.13% 57.27% 52.22% 65.33% 64.82%
Noncontrolling interest 0.08 0.07 0.08 0.07 0.06 0.27 0.26 0.27 0.28 0.28 0.26 0.26 0.27 0.28 0.31 0.27 0.28 0.29 0.28 0.29
Total equity 62.53% 61.13% 61.82% 61.80% 61.18% 60.26% 59.40% 57.97% 63.87% 62.78% 62.97% 63.11% 62.67% 62.66% 63.31% 58.40% 57.55% 52.51% 65.61% 65.11%
Total liabilities and equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Allergan Inc. current liabilities as a percentage of total liabilities and equity increased from Q2 2014 to Q3 2014 but then decreased significantly from Q3 2014 to Q4 2014.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Allergan Inc. non-current liabilities as a percentage of total liabilities and equity increased from Q2 2014 to Q3 2014 but then decreased significantly from Q3 2014 to Q4 2014.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Allergan Inc. total liabilities as a percentage of total liabilities and equity increased from Q2 2014 to Q3 2014 but then decreased significantly from Q3 2014 to Q4 2014.
Total Allergan, Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Allergan Inc. total Allergan, Inc. stockholders’ equity as a percentage of total liabilities and equity decreased from Q2 2014 to Q3 2014 but then increased from Q3 2014 to Q4 2014 exceeding Q2 2014 level.